XINTELA RECRUITS RICKARD MOSELL AS HEAD OF BUSINESS DEVELOPMENT
On 12 September 2016, Xintela announces that Rickard Mosell has been recruited
as Head of Business Development from October 1, 2016. Rickard Mosell will leave
his current position as CEO of Ideon Innovation and will be responsible for
Xintelas business development and financing. Rickard Mosell will also be a
member of Xintelas management team.
Rickard Mosells acedemic background is in law and he has broad experience of
innovation and business operations. Amongst other roles, he has been the CEO
for Ideon Science Park in Lund - comprising approximately 370 companies with 2
700 employees - and his most recent appointment as CEO for the business
incubator Ideon Innovation. Overall, Rickard Mosell has been an advisor in
business development, financing, marketing and legal aspects to approximately
10 000 start-up projects.
- It is vital going forward that Xintela has a strong focus on business
development and we are confident that Rickard has the experience, the
competence and the network needed. He has long been a driving force in
business development, sales and communication and has built up an extensive and
significant network, both nationally and internationally. We are very happy to
welcome Rickard back to Xintela, says the companys CEO Evy Lundgren-Åkerlund.
Rickard Mosell has previously been closely involved with Xintela. In 2009, he
was a co-founder of the company and thereafter, until 2014, he was a member of
the board.
- I am really looking forward to being part of Xintela again and helping to
develop a clear commercial focus for this exciting company. Of course it makes
things easier that I already have a good understanding of the operations and
that I know Evy previously, says Rickard Mosell.
Rickard Mosell will also join Xintelas management team which currently
comprises the companys CEO Evy Lundgren-Åkerlund, Research Director Carl-Magnus
Högerkorp, Finance Director Gunnar Telhammar and strategic advisor (and
Chairman of the Board) Gregory Batcheller.
2016-09-12
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel:+46 70-329 18 71
E-mail: evy@xintela.se mailto:evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se http://www.xintela.se/
Queries regarding trading with Xintela shares and warrants will be answered by
the companys Certified Adviser, Consensus Asset Management AB. Telephone: +46
31-745 50 00.
Media and Investor Relations related queries should be directed to:
Adam Lindblom, Laika Consulting
Tel: +46 73-062 20 13
E-mail: adam.lindblom@laika.se mailto:adam.lindblom@laika.se
www.laika.se http://www.laika.se/
The following documents can be retrieved from beQuoted
Xintela Pressrelease 2016-09-12 English.pdf -
http://www.bequoted.com/beQPress/download.asp?Id=18697
This information is information that Xintela AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. This information was
submitted for publication through the agency of the contact persons set out
above on 12 September 2016, at 2:00 p.m CET
About Xintela
Xintela AB (publ) is a Swedish biomedical company active in the fields of
regenerative medicine and cancer, with a focus on cartilage damage and brain
tumours. The key to Xintelas business is the Companys patented marker
technology, XINMARK(tm). Xintelas markers are specific proteins which sit as
"recognition flags" on certain cell surfaces. The markers make it possible to
identify and quality assure cartilage cells and stem cells and also to select a
certain type of stem cells which can develop into cartilage cells. Through this
technology, Xintela can, in a unique way, quality assure stem cells for the
repair of damaged cartilage. The XINMARK(tm)-technology makes it also possible
to direct antibody treatment to cells in glioblastoma brain tumours with the
goal to slow down tumour growth. Xintela is listed on Nasdaq First North since
22 March 2016. Xintelas Certified Adviser at Nasdaq First North is Consensus
Asset Management AB.
